Pea Protein and Postprandial Response (PEA)

NCT ID: NCT01215370

Last Updated: 2011-09-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective is to investigate the postprandial effect of arginine-rich protein (i.e. pea-protein) on metabolic control, inflammation and endothelial function after a high-fat meal in subjects with characteristics of the metabolic syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Arginine is potential interesting considering the metabolic syndrome. Studies so far indicated both long-term effects, as well as acute - postprandial - actions; especially when metabolism is already challenged, e.g. in diabetic patients or after a high-fat meal. If arginine-rich proteins are equally effective is not known. Therefore we are interested in the effect of (arginine rich) protein on postprandial (dys)metabolism, inflammation and endothelial function, within 6 hours after a meal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-fat shake with Pea protein

Shake containing 95 gram of fat, additive 30 gram pea protein

Intervention Type OTHER

High-fat shake with Pea protein hydrolysate

Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate

Intervention Type OTHER

High-fat shake - Control

Shake containing 95 gram of fat, no protein additive

Intervention Type OTHER

High-fat shake with Gluten protein

Shake containing 95 gram of fat, additive 30 gram gluten protein.

Intervention Type OTHER

High-fat shake with Gluten protein hydrolysate

Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Experimental Experimental Control Experimental Experimental

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male gender
* central obesity: waist circumference ≥94 cm

plus any one of the following four factors:

* raised triglyceride level: ≥1.7 mmol/L;
* reduced high-density lipoprotein (HDL) cholesterol: \<1.03 mmol/L
* raised blood pressure: systolic blood pressure ≥130 mmHg or diastolic BP ≥85 mmHg or use of blood pressure lowering medication
* raised fasting plasma glucose ≥ 5.6 mmol/L


* age 45-70 years
* body weight should be stable for 3 months
* stable exercise habits during the last 6 months, and not participating in any vigorous exercise program

Exclusion Criteria

* tobacco smoking
* (undiagnosed) diabetes - but not impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) as evaluated by an oral glucose tolerance test at screening
* active hearth disease, i.e. history of myocardial infarction or angina pectoris
* following, or have recently followed a (weight-loss) diet
* drug uses knowing to interfere with the objectives of the study
* oral corticosteroids, lipid-lowering drugs (statins)
* allergic to cow milk / dairy products or gluten
* vegetarians
* received inoculations within 2 months of starting or planned to during the study
* donated or intended to donate blood 2 months before till two months after the study
* abuse of drugs and/or alcohol
* participation in another biomedical study within 1 month before the first screening visit
* not agreeable to be informed about possible distorted blood values which could be found by screening
Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wageningen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wageningen University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marco Mensink, Dr

Role: STUDY_CHAIR

Department Human Nutrition, Wageningen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wageningen University, Division of Human Nutrition

Wageningen, Gelderland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL3207808110

Identifier Type: OTHER

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Peas in Soup on Blood Glucose Control
NCT03306862 ACTIVE_NOT_RECRUITING NA
Effects of Peas on Blood Glucose Control
NCT02552823 ACTIVE_NOT_RECRUITING NA